Abstract | A hypercaloric diet combined with a sedentary lifestyle is a major risk factor for the development of insulin resistance, type 2 diabetes mellitus (T2DM) and associated comorbidities. Standard treatment for T2DM begins with lifestyle modification, and includes oral medications and insulin therapy to compensate for progressive β-cell failure. However, current pharmaceutical options for T2DM are limited in that they do not maintain stable, durable glucose control without the need for treatment intensification. Furthermore, each medication is associated with adverse effects, which range from hypoglycaemia to weight gain or bone loss. Unexpectedly, fibroblast growth factor 1 (FGF1) and its low mitogenic variants have emerged as potentially safe candidates for restoring euglycaemia, without causing overt adverse effects. In particular, a single peripheral injection of FGF1 can lower glucose to normal levels within hours, without the risk of hypoglycaemia. Similarly, a single intracerebroventricular injection of FGF1 can induce long-lasting remission of the diabetic phenotype. This Review discusses potential mechanisms by which centrally administered FGF1 improves central glucose-sensing and peripheral glucose uptake in a sustained manner. Specifically, we explore the potential crosstalk between FGF1 and glucose-sensing neuronal circuits, hypothalamic neural stem cells and synaptic plasticity. Finally, we highlight therapeutic considerations of FGF1 and compare its metabolic actions with FGF15 (rodents), FGF19 (humans) and FGF21.
. The current pharmacological paradigm of T2DM management involves sequential attempts at normo glycaemia with oral agents, which often culminate in the need for patients to be placed on insulin to approach glycaemic control. An increasing number of new drugs and drug classes have become available to manage the disease; however, despite initial promise, each option remains hampered by a combination of adverse effects and lack of longterm efficacy 4, 5 . In all, the disease has largely remained a chronic and progressive condition. Although stem cellderived βcell replacement could possibly cure diabetes mellitus, successful metrics have not been met. With no widely effective treatment, let alone cure, available and rates of the disease continuing to rise alongside costs, the toll of T2DM seems to be unyielding.
In this regard, fibroblast growth factor 1 (FGF1) has emerged as a promising solution to the diabetes dilemma. Although FGF1 is considered to be a well established component of processes such as embryonic development, wound healing, neurogenesis and angio genesis, the wholebody Fgf1knockout mouse shows no deficiency in any of these processes 6, 7 . Indeed, only in 2014, was FGF1 shown to be a metabolic hormone crucial for the management of nutrient stress, glycaemic control and insulin sensitivity 8 . Fgf1knockout mice develop marked hyperglycaemia and insulin resist ance when challenged with a highfat diet (HFD). In ob/ob and db/db mice or dietinduced obesity (DIO) models, peripheral delivery of a single dose of recom binant FGF1 (rFGF1) can normalize blood levels of glu cose within hours, without inducing hypo glycaemia 8 . Chronic treatment similarly achieved sustained glucose lowering, with insulin sensitization observed within 3 weeks of initiating therapy 8 ; no desensitization to the effects of FGF1 was observed. This work has brought FGF1 to the forefront as a potential new therapeu tic approach for insulin sensitization and treatment of T2DM.
Following on from these original findings, a single central injection of rFGF1 in mice rendered diabetic by DIO and lowdose streptozotocin (STZ) was shown to induce normoglycaemia for up to 18 weeks after injection 9 . Longlasting glucoselowering effects were also observed after a single central injection of rFGF1 in leptindeficient ob/ob and leptin receptordeficient db/db (on a BKS background) mice, as well as in leptin receptordeficient Zucker diabetic fatty rats 9 . This cen tral effect was associated with increased hepatic content of glycogen and was independent of weight loss, reduced food intake, increased insulin sensitivity or increased levels of insulin (FIG. 1) .
Although peripherally injected FGF1 could poten tially signal centrally, it is less likely to act systemically than centrally injected FGF1. This raises the challeng ing question as to the potential mechanism underlying glycaemic control by the central nervous system (CNS) and whether this can be exploited for therapeutic use. In this Review, we discuss the foundation for FGF1 and the CNS in glycaemic control and how these two might interact to jointly improve glucose regulation. We then weigh the metabolic actions of FGF1 against other met abolically active FGFs. We conclude by noting factors that must be evaluated in the further development of FGFbased therapeutics for clinical medicine.
Role of FGF1 in glucose control

Feeding suppression
Initial evidence for a central role of FGF1 in feeding suppression stemmed from reports of a postprandial increase in levels of FGF1 and FGF2 in the cerebro spinal fluid of rats [10] [11] [12] . In this context, glucose was identified as the crucial cue, as both intraperitoneal and intra cerebroventricular (ICV) glucose injections were sufficient to induce FGF1 release into the cerebrospinal fluid 10 . Moreover, ventricular microinfusion of FGF1 and FGF2 revealed a dosedependent suppression of feeding in rats 10, 12, 13 . FGF1 acts in an autocrine and/or paracrine manner, as binding to heparan sulfate proteoglycans prevents it from entering the circulation, thus necessitating its local production 14, 15 . In the brain, ependymal cells lining the ventricular space constitute the main source of FGF1 production 10, [16] [17] [18] . Upon glucose stimulation, FGF1 is secreted by ependymal cells and induces the expres sion of the early response markers Fos (which encodes FOS) and Hspb1 (which encodes heat shock protein β1) selectively in glucosesensing tanycytes lining the ventral part of the third ventricle and in periventricular hypo thalamic astrocytes 9, 10, 19, 20 . The lack of FGF1induced changes in Fos expression in hypothalamic neurons points to tanycytes and astrocytes as the primary cel lular targets of secreted FGF1 in the brain 9, 19, 20 . Fos and Hspb1 induction in astrocytes temporally correlates with the feeding inhibition elicited by ICV infusion of FGF1, which is strongest within the initial 2-6 h but sus tained for 24 h 11, 19, 20 . FGF receptor 1 (FGFR1) is widely expressed throughout the hypothalamus 21, 22 ; internali zation and retrograde transport of radioactively labelled 125 IFGF1 and 125 IFGF2 has been observed in distinct neuronal populations 18 h, but not 5 h, after ICV admin istration of FGF1 (REF. 23 ). FGF1 has therefore been pos tulated to suppress food intake in two phases, an early response mediated mainly by hypothalamic astrocytes followed by a neurondependent late response 19 . Based on the aforementioned findings, the initial neg ative impact of FGF1 on feeding behaviour is plausibly mediated by its activation of periventricular astrocytes, which in turn are known to modulate the activity of ano rexigenic proopiomelanocortin (POMC) and orexigenic agoutirelated peptide (AgRP) neurons in the arcuate nucleus (ARC) [24] [25] [26] [27] . In addition, the lateral hypothalamic area (LHA) has been prominently implicated in the hypophagiainducing actions of FGF1. Namely, neurons expressing orexin and melaninconcentrating hormone within the LHA are considered important players in the regulation of food intake, arousal and motivated behav iour 28 . In rats, 125 
IFGF1 and
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IFGF2 are internalized by LHA neurons after ventricular infusion 23 . Moreover, bilateral LHA administration of antiserum raised against either FGF1, FGF2 or their receptor FGFR1, induces hyperphagia 10, 29 . At the cellular level, FGF1 and FGF2 cause a protein kinase C (PKC)dependent inhibition of a significant fraction of glucosesensitive LHA neu rons 10 . The LHA thus conceivably continues to suppress food intake, for a limited time window, after the initial activation of astrocytes by FGF1 has worn off.
Glucose lowering
In contrast to the feeding effect, the glucoselowering effect of FGF1 in diabetic settings was discovered only in the past few years, and attempts to identify its cellular and molecular mechanisms are still in the early stages 8, 9 . In addition, the food suppression component of both the central and peripheral FGF1 response is transitory, whereas the glucoselowering effect is persistent 8, 9 . In the periphery, the glucoselowering effect of injected or endogenous FGF1 is in part mediated by the FGF1-FGFR1 signalling cascade. Adipose tissue has been identified as the primary target site of 'endocrin ized' rFGF1, as AP2-Cre driven Fgfr1 ablation negates its glucoselowering effects in 8month old DIO mice 8 . Notably, endogenous FGF1 is induced during the fed state in adipose tissue by the nuclear receptor perox isome proliferatoractivated receptor γ (PPARγ), the same nuclear receptor targeted by insulinsensitizing thiazolidinedione (TZD) drugs 30 . However, in contrast Endocrinized rFGF1 has been suggested to limit hypothalamic-pituitary-adrenal (HPA) axis activity and produce normoglycaemia in rats with STZinduced T1DM by decreasing hepatic production of glucose, hepatic levels of acetyl CoA and lipolysis 31 . However, the idea that suppression of the HPA axis is sufficient to counteract diabetic hyperglycaemia is still contro versial 32, 33 . Moreover, central injection of rFGF1 in the lateral or third ventricle of ob/ob mice profoundly lowers blood levels of glucose, and it does so without affecting plasma levels of corticosterone 9 . A concordant explana tion for both models would be that peripheral and central injections of rFGF1 achieve similar effects through differ ent paths 8, 9 . Thus, peripheral action would be initiated by an FGFR1 signalling cascade in fat, whereas central FGF1 would act through an astrocyte-glial-neuronal circuit.
A second parallel between peripheral and central FGF1 action is that each of them seems to rely on intact insulin signalling, as shown by a lack of efficacy in DIO mice treated with the insulin receptor antagonist S961 or in highdose STZtreated mice with βcell ablation 9 . In addition, both peripheral and central injections sus tain glucose lowering without causing hypoglycaemia 8, 9 . Nonetheless, and despite these parallels, central and peripheral mechanisms reflect significant differences. A single peripheral injection of FGF1 in diabetic rodents triggers acute glucose lowering (within hours) and mul tiple doses promote insulin sensitization in 3 weeks 8 . By contrast, a single ICV injection of FGF1 lowers glucose in about a week and sustains this effect beyond 16 weeks, without insulin sensitization 9 . Notably, whereas both FGF1 and FGF2 have been linked to the central regulation of food intake, only FGF1 displays glucoselowering effects after periph eral injection in ob/ob mice 8 . This finding is however in contrast to a more recent (2016) metabolomics study, in which intravenous injection of FGF2 into STZinduced diabetic rats lowered blood levels of glucose 34 . In addi tion, to our knowledge, data describing the effects of central injection of FGF2 in diabetic animals are not currently available. Notwithstanding this caveat, devi ating functional repertoires of FGF1 and FGF2, despite overlapping receptor specificity, could be explained by the possibility that distinct intracellular pathways are engaged following FGF1 and FGF2 binding to their receptor, evoked by characteristic structural changes in the intracellular receptor domains 35 . The sustained normalization of blood levels of glucose in diabetic animals after a single ICV injection of FGF1, in the absence of hypoglycaemic episodes, clearly war rants further mechanistic investigations as an attractive alternative to current treatment methods. These results lead us to postulate the existence of an as yet unknown mechanism by which a single central injection of FGF1 might permanently increase peripheral uptake of glucose by the liver and skeletal muscle 9 .
Central FGF1 effects -possible mechanisms
Glucose-sensing neurons
The significance of the brain in peripheral glucose homeostasis was first demonstrated by Claude Bernard 36 in 1855, who showed that destruction of the hypothala mus in dogs induces hyperglycaemia. Almost 100 years later, John Mayer 37 proposed the existence of specialized hypothalamic cells that monitor changes in glucose con centrations and commence a corresponding chemical or electrical response. Definite evidence for the existence of these glucosesensing neurons (GSNs) was later pro vided by the identification of hypothalamic neurons that alter their firing activities in response to changes in extracellular glucose concentrations 38, 39 . Since then, several specific GSN populations have been identified, mainly within the hypothalamus and different brainstem structures 40, 41 . Depending on whether their firing frequency is increased or decreased in response to rising extracellular levels of glucose, they are termed glucoseexcited (GE) or glucoseinhibited (GI) neu rons, respectively 42, 43 . Neurons can either utilize glucose directly or take it up in the form of lactate, which is produced by neighbouring astrocytes. During eugly caemia, brain levels of glucose are believed to be in the range of 0.7-2.5 mM, reaching a maximum of 4.5 mM during severe plasma hyperglycaemia and dropping to 0.2-0.3 mM during plasma hypoglycaemia 44, 45 . Glucose sensing in GE neurons occurs in a way that is mechanis tically similar to that in pancreatic β cells 46 . High extra cellular levels of glucose cause an increased intracellular ATPtoADP ratio, closure of ATPsensitive potassium channels, subsequent depolarization of the plasma mem brane and finally opening of voltage sensitive calcium channels 42, 47, 48 . However, additional alternative glucose sensing mechanisms have been proposed in GE neurons such as the transient response (TRP) channels 49 or the dimeric G proteincoupled sweet receptor T1R2-T1R3 (REF. 50 ). Cellular metabolism dependent and independ ent mechanisms have been reported for GI neurons. In GI neurons of the ventromedial nucleus of the hypo thalamus (VMH), firing activity is negatively regulated by high levels of glucose that inhibit the AMPactivated kinase (AMPK), which leads to Cl − channel opening and hyperpolarization 51, 52 , whereas the existence of phar macological glucose detectors has been proposed for orexin neurons 53 . Within the hypothalamus, GE and GI neurons have been identified in the ARC, the ventromedial hypo thalamus, the paraventricular hypothalamus and the LHA 43 . Depending on their anatomical and neurochem ical characteristics, the physiological response of GSNs is likely to vary, but altered reproduction, food intake and energy expenditure have so far been shown to be included in their functional repertoire 43 . In particular, ample evidence exists for the role of GI neurons, most notably in the VMH [54] [55] [56] [57] , in the sympathetic counter regulatory response to hypoglycaemia, which triggers the secretion of glucagon and adrenaline from pancre atic α cells and the adrenal medulla, respectively, as well as hepatic production of glucose 58, 59 . Of all the GSN populations, only the LHA has so far been directly mechanistically implicated in FGF1 actions. As eluded to earlier, FGF1 application on LHA neurons decreased neuronal activity in 66% of GSNs and only in 16% of nonGSNs 10 . At the same time, none of the tested VMH neurons responded to FGF1. Within the LHA, orexin neurons are inhibited, whereas neu rons expressing melaninconcentrating hormone are excited by physiological changes in glucose 60, 61 , which suggests that orexin neurons are the likely targets of FGF1 actions. Of note, reciprocal synaptic connec tions exist between orexin neurons and neurons in the ARC, and the orexin receptors OX1R and OX2R are widely expressed in neurons of the ARC, VMH, paraventricular hypothalamus and dorsomedial hypo thalamus (DMH) 62, 63 . In particular, orexin neurons have been shown to control, at least in part via the VMH, the sympathetic output to the liver and skeletal muscles, which modulates glucose production and uptake, respectively 64, 65 . However, the persistent nature of the glucoselowering effect, long after cellular signalling induced by exogenous FGF1 has abated, clearly sug gests that additional mechanisms apart from the mere modulation of the activity of existing neuronal networks are at work.
Tanycytes -neurogenesis
Within the hypothalamus, tanycytes populate the floor and ventrolateral aspect of the third ventricle, which places them in immediate proximity to the median eminence, ARC, VMH and DMH 66, 67 . Tanycytes pos sess a long process that projects into the parenchyma, allowing them to come into close contact with neurons of the hypothalamic nuclei, thus potentially regulat ing neuroendocrine output and energy homeostasis 68 . Tanycytes are able to sense altering plasma levels of glu cose and respond to focally applied glucose by changes in intracellular Ca 2+ signalling 69, 70 . Importantly, tany cytes constitute a hypothalamic pool of neurologic pro genitor cells in the adult nervous system 66, [71] [72] [73] , which holds particular relevance when considering the mecha nistic ramifications of the longlasting glucose lowering effect of FGF1. Lineagetracing experiments have revealed that the neuronal progeny of tanycytes pop ulates mainly the ARC, but also the VMH, DMH and LHA 71, 72 . Lineagetraced tanycytes have also been shown to give rise to astrocytes and proliferating progenitor cells in the hypothalamic parenchyma 71, 72, 74 . Metabolic stress associated with obesity and diabe tes mellitus compromises the functional integrity of the hypothalamic circuits that mediate inflammatory and neurodegenerative events, which ultimately con tributes to the derailment of energy homeostasis 75 . In mice, hypothalamic inflammation is evident within the first few days of beginning a HFD, and prolonged HFD exposure leads to a loss of POMC neurons and apopto sis in mature neurons, which underlines the exceptional vulnerability of the hypothalamus to overnutrition [76] [77] [78] . The importance of neural regeneration originating from progenitor cells residing in the periventricular zone has been demonstrated most dramatically by the gradual ablation of AgRP neurons, which is compen sated for by de novo formation of neurons within the hypothalamic parenchyma 79 , whereas acute ablation of AgRP neurons in adult mice causes severe anorexia and death 80, 81 . Similarly, weight loss induced by injection of ciliary neurotrophic factor in mice is counteracted by hypothalamic neurogenesis 73 . At the other end of the spectrum, leptin deficiency or DIO have been shown to disrupt neural stem cell proliferation in adult mice, thus preventing the adaptive remodelling of the ARC 77,82 . Conversely, shortterm HFD feeding is reported to pro mote neurogenesis in tanycytes of the median eminence at preadult ages 83 , potentially indicating an initial compensatory attempt.
Analogous to other neural stem cell populations, tanycyte proliferation is stimulated by insulinlike growth factor 1 (IGF1) and FGF2 (REFS 72, 84 neurogenesis to repair neural circuits that have deterio rated as a consequence of dietary insults (FIG. 2) . Injection of a relatively small number of enhanced green fluores cent protein (eGFP)labelled leptin receptor (LepR) positive neurons (isolated from embryonic day 13.5 embryos) into the hypothalamus of up to 1week old LepRdeficient db/db mice was sufficient to cause a marked reduction in blood levels of glucose that per sisted for 9 weeks and 13 weeks after transplantation 85 . Mirroring the effect of central injection of FGF1 in ob/ob mice, rescue of peripheral glucose homeostasis in adult mice occurred without changes in plasma levels of insulin 85 . Tracing the fate of the injected eGFPlabelled neurons established their synaptic and functional inte gration into hypothalamic neurocircuits, thereby prov ing the receptiveness of hypothalamic neuronal circuits to cellmediated repair following metabolically inflicted damage 86 .
Synaptic plasticity
Synaptic plasticity has been alluded to as a potential mechanism to explain the longlasting glucoselowering effect of FGF1 (REF. 9 ). Such plasticity involves changes in synaptic activity and connectivity, thereby providing a mechanism by which neuronal circuits can adapt to and maintain responsiveness across a wide range of stimuli 87, 88 . In contrast to the wellestablished role of synaptic plasticity in learning and memory formation, its function in the hypothalamic neuronal circuits that control feeding behaviour has only recently been dis covered 89, 90 . The laboratory of Tamás Horváth 91 was the first to show that neurons of the ARC alter their synap tic connections in response to physiological signals of nutrient availability such as ghrelin and leptin, which signal food deprivation and satiety, respectively. Later, the same group reported that this phenomenon is not an exclusive feature of the ARC. Leptin was found to Pathological changes in peripheral organs are accompanied by hypothalamic inflammation and reduced remodelling of hypothalamic neurocircuits. In pathological conditions such as diabetes mellitus and obesity, astrocytes undergo a process of hypertrophy and hyperplasia, commonly termed reactive astrocytosis or astrogliosis. Increasing neuronal insults, such as inflammatory or excitotoxicity signals contribute to a dysfunctional neuronal firing state and even neurodegeneration. Although rare in adult individuals, neurogenesis, originating from tanycytes in the third ventricular lining or periventricular astrocytes, is believed to amend some of the inflicted damage. However, aggravating metabolic conditions reduce the neurogenic potential of hypothalamic neuroprogenitor cells. Overall, this contributes to decreased central glucose sensing and peripheral glucose clearance. c | Owing to the limited data currently available, one can only speculate about the actions of fibroblast growth factor 1 (FGF1) within this network. Potentially, central FGF1 remedies the debilitated hypothalamic state in diabetes mellitus by restoring health (or number) of glucose-sensing neurons, (transiently) inducing neurogenesis, suppressing reactive astrocytes and restoring synaptic functionality, which ultimately leads to the observed restoration of normoglycaemia. The lower panel shows the structure of human FGF1 (PDB ID 2HZ9).
additionally regulate the synaptic organization of orexin neurons in the LHA 92 , and ghrelin was shown to modu late synapse formation in the hippocampus 93 and ventral tegmental area 94 . Furthermore, hypercaloric challenges in the form of a HFD were also found to induce synaptic remodelling in the ARC 95, 96 . Interestingly, deviations in the synaptic inputs onto satietypromoting POMC neu rons might contribute to the difference in susceptibility of inbred mouse strains to DIO 95 . Depending on the energy state of the organism, syn apses are formed or removed, and the number of den drites, as well as the amount of excitatory and inhibitory inputs, can be varied 89 . Synaptic adaptations are also accompanied by intracellular plasticity, encompassing, for example, mitochondrial fission or fusion in neurons of the ARC and the VMH [97] [98] [99] , or uncoupling of mito chondrial respiration via mitochondrial uncoupling protein 2 in ARC neurons 100 . In AgRP neurons, synaptic plasticity in the response to ghrelin has been shown to involve a presynaptic AMPKdependent positive feed back mechanism that allows the glutamatergic activa tion of AgRP neurons to persist for hours after ghrelin removal and its resetting by leptin administration 101 . Astrocytes too have been connected to the modulation of synaptic plasticity 102 , by contacting and stripping dysfunctional synapses, releasing glial transmitters and taking up neurotransmitters from the synaptic cleft, thus representing the main defence against excitotoxicity and other neuronal insults 103, 104 . The occurrence of reactive astrogliosis in response to both acute and chronic high fat feeding 76, 95 could therefore be potentially damaging to the synaptic plasticity of ARC neurons 105 . Additional support for the role of astrocytes in synaptic plasticity comes from the findings that hypothalamic astrocytes respond to leptin by changing levels of glutamate and glucose transporters 106 . Despite some initial evidence, if and how FGF1 affects synaptic plasticity to induce remission of diabetes mellitus have yet to be determined. Some connections between FGFs and synaptic plasticity, albeit not in the hypothalamus, have already been suggested by earlier studies. FGF2 was reported to promote axonal growth and sprouting after injury 107 and to influence hippo campal synaptic plasticity 108 . FGF1 has been found to modulate synaptic plasticity of neurons in the corticostriato-pallidal pathway that involves the synergetic activation of FGFR1 and the G proteincoupled α2A adrenergic receptor 109 . Costimulation of both receptors caused a marked synergistic increase in neurite forma tion and spine density in striato-pallidal neurons, which involved a rapid and longlasting phosphorylation of extracellular signalregulated kinases 1 and 2 (ERK1/2) mediated by mitogenactivated protein kinase/ERK kinases 1 and 2 (MEK1/2) 109 . With regards to the enduring nature of the FGF1driven normalization of blood levels of glucose in diabetic animals, the hysteresis effect, which enables sus tained activation of AgRP neurons even hours after the initial ghrelin stimulus, is particularly intriguing 101, 105 . Whether central injection of FGF1 elicits a similar sig nal, causing longlasting changes in synaptic plasticity of yettobeidentified neuronal subpopulations and triggering the observed metabolic improvements, is an intriguing possibility. Given their activation by FGF1 (REFS 9, 19, 20) and their effect on neuronal health and functionality, astrocytes represent one avenue by which FGF1 could potentially affect neuronal plasticity in the hypothalamus (FIG. 2) .
Central insulin signalling
Considering that FGF1mediated glucose lowering depends on functional insulin signalling, it is impor tant to note that all potentially involved central mech anisms outlined earlier are vulnerable to diminishing insulin signalling. Ablation of insulin receptor signal ling in neurons of the ARC 110, 111 , the ventral tegmental area 112 or the dorsal vagal complex in the brainstem 113 causes either impaired glucose homeostasis or obesity, whereas deletion of the insulin receptor in steroidogenic factor 1expressing neurons of the VMH protects against DIO 114, 115 . In 2016, deletion of the insulin receptor in astrocytes was shown to negatively affect their function and morphology, causing changes in glucose transport across the blood-brain barrier and ultimately impeding ARC neurons from monitoring and responding to sys temic changes in levels of glucose 25 . Moreover, as dis cussed earlier, DIO and hyperinsulinaemia put a brake on neurogenesis in the hypothalamus 77, 82 , which could imply that insulin signalling must not come to a complete halt in order for a potential neurogenic effect of FGF1 to occur. Finally, the role of central insulin resistance in neuronal plasticity has become increasingly recog nized as a potential cause of the development of cogni tive impairment, which involves synapse deterioration and neurodegeneration 116, 117 .
Peripheral glucose uptake
Additional studies are required to address how ICV FGF1 induces increases in peripheral glucose clearance in the liver and skeletal muscle, without affecting circu lating levels of insulin, glucoseinduced insulin secre tion, insulin sensitivity or hepatic glucose output. In general, GSNs are best known for their control of both sympathetic and parasympathetic branches of the auto nomic nervous system 40 . In response to altering levels of glucose, the range of actions mediated by the parasym pathetic autonomic nervous system includes the stimu lation of pancreatic βcell proliferation, insulin secretion and the secretion of glucagon during hypoglycaemia. Sympathetic activity stimulates glucagon secretion and inhibits insulin secretion, promotes thermogenesis in brown adipose tissue, stimulates adrenaline secretion by the adrenal glands, enhances lipolysis in white adi pose tissue and regulates hepatic production of glu cose 40, 118 . However, there are some indications that the brain has the capacity to lower blood levels of glucose via both insulindependent and insulinindependent mechanisms 119 . In rats, electrical stimulation of VMH neurons or leptin injection into the VMH, but not into the LHA, has been shown to increase peripheral glucose uptake, including that in skeletal muscle, independently of circulating levels of insulin; these effects are abolished by blockade of the sympathetic autonomic nervous sys tem 120, 121 . Furthermore, leptin has been shown to rescue and restore normoglycaemia in insulindeficient mice by reducing hepatic production of glucose while increasing tissue glucose 122, 123 . Metabolic improvements, originating from central injections of FGF1, are also possibly caused by changes in the gut-liver-brain axis 119, 124 . In particular, the hepatic portal vein has a major role in hepatic and peripheral glucose disposal 125, 126 . The portal vein is heavily inner vated by vagal afferents that express nutrient sensors and relay information to higher brain centres 126 . Glucose delivery directly into the portal vein increases net hepatic glucose uptake by a neural mechanism, as denervation of the liver or intraportal infusion of adrenergic block ers and acetylcholine reduces or increases, respectively, net hepatic glucose uptake in response to portal glucose delivery 125, 127, 128 . Nevertheless, FGF1 is likely to engage novel (neu ral) glucoseregulatory mechanisms or combinations thereof, as similar findings have so far not been reported. Likewise, the involvement of a humoral factor cannot be excluded at this stage.
Barrier to FGF1 success -mitogenicity Although isolated as an in vitro growth factor, wildtype FGF1 presents the issue of potential in vivo mitogenic ity. However, wholebody knockout of Fgf1 causes no change in tissue growth, and the only known defects are adipose inflammation and a severe form of diabe tes mellitus in response to dietary stress 30 . In addition, several transgenic mouse lines constitutively overex pressing FGF1 do not present with tumours or organ growth, which suggests in vivo safety over long periods of exposure [129] [130] [131] . Gene expression array studies have found increased levels of FGF1 in breast, prostate and ovarian cancers, but a contribution beyond correlation has not been established [132] [133] [134] . Perhaps more impor tantly, targeted structure-function studies clearly sug gest that the mitogenic and glucoselowering potentials of FGF1 are separable. FGF1induced growth in vitro is predominantly associated with FGFR3 and FGFR4, whereas glucoselowering is mediated by FGFR1 (REFS 8, 135, 136) . Indeed, FGF1 binding to FGFR3 and FGFR4 can be greatly diminished by mutations and/or deletions in FGF1 that leave its glucoselowering poten tial fully intact 8 . Thus, the potential for a therapeutically viable, fully nonmitogenic human FGF1 variant seems to be highly plausible. Such a variant could be useful in the context of either a peripheral or central therapeutic injection strategy.
Alternatives to FGF1
As a class, FGFtargeted pharmaceuticals are not com pletely new prospects. Various members of the FGF family have been explored to treat conditions beyond metabolic disorders. Intravenous recombinant human FGF7 is an FDAapproved treatment for oral mucosi tis 137 , whereas other members of the FGF family are being developed for the treatment of ischaemia, cerebro vascular disease and cardiovascular disease 136 .
In addition, various FGFR modulators are in clinical trials for cancer treatment 138 . Although the high poten tial benefits of a nonmitogenic FGF1 therapy for the treatment of diabetes mellitus and its complications are tantalizing, the actions of FGF1 must still be validated in clinical trials 139, 140 . Other FGFs, namely, FGF15 (rodents), FGF19 (humans) and FGF21, are known factors involved in energy homeostasis. To a certain extent, FGF19 and FGF21 have shown metabolic benefits upon central injection (TABLE 1) . ICV injections of FGF19 in both ob/ob and DIO rodents yielded insulinindependent glucose lowering effects through a CNSmediated mechanism, with acute improvements occurring within a few hours of injection [141] [142] [143] [144] . ICV injection of FGF21 to DIO rodents garners metabolic benefits in the form of increased energy output and insulin sensitivity linked to weight loss 145, 146 . In each case, the FGF effect either required multiple injections or did not have duration compara ble to a onetime central injection of FGF1. In addition, concern remains regarding the adverse effects of therapy with FGF19 or FGF21. FGF19 overexpression has been shown to promote hepatocellular carcinoma 147, 148 , and systemic administration of FGF21 has not been fully divested from noticeable bone loss 149 . However, non mitogenic FGF19 variants have been developed, and acute benefits of FGF21 are currently being explored 136 . At this point, whether central adverse effects mirror these peripheral ones is unclear.
Clinical considerations for FGF1
Therapeutically, an intracranial injection might not be necessary to achieve a robust central effect. Achieving normoglycaemia resembling that of central injection of FGF1 could possibly occur via an intranasal route. Derivatives of FGF1 given intranasally are able to locally induce angiogenesis and neuronal survival in rodents, with penetrance across the blood-brain barrier greatly enhanced when attached to defined transporter pro teins 150, 151 . Migration into the CNS is believed to occur through a combination of movement along the olfac tory nerve, nasal mucosa capillaries and through cere brospinal fluid via the cribriform plate 150, 152 . Intranasal delivery of large biologic proteins is conceptually advan tageous; however, this approach has yet to be adopted in an approved prescription drug. Also, whether a single nasal injection would be sufficient to confer the equivalent longterm benefits seen with central injec tion is unclear. In addition, even if sufficient levels of FGF1 could be transferred into the CNS, this might or might not be optimal for key target sites. Developing a therapeutically effective FGF1 targeted to the CNS by means other than direct intracranial application would first require a better understanding of the specific brain regions mediating the metabolic actions of the peptide. Nonetheless, the idea of a noninvasive route remains appealing in that it would greatly improve accessibility, as selfdelivery of doses would be possible.
Controlling blood glucose by either peripheral or central delivery will go far to alleviate shortterm com plications of diabetes mellitus, such as hypoglycaemic episodes, hyperosmolar hyperglycaemic states, diabetic ketoacidosis and diabetic comas. Ultimately though, the success of any intervention to treat or possibly cure dia betes mellitus will rely on more than regulating levels of glucose. The value of any solution must also be judged by its ability to limit chronic complications of diabetes mellitus, both microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (cardiovascular disease). Traditionally, the standard of treatment has focused heavily on achieving glucose, and in turn HbA 1c targets. Current evidence indicates that microvascular complications can be greatly limited by reaching des ignated HbA 1c goals. However, the same clear, direct benefit of consistent glycaemic control in risk reduction as measured by HbA 1c cannot be applied as confidently to macrovascular concerns [153] [154] [155] . It must be noted that, in either case, increasing evidence points towards large intraday fluctuations in glucose, specifically in post prandial glucose, as a driver of complications, independ ent of chronic hyperglycaemia. These acute changes are believed to create periods of exacerbated inflammation, oxidative stress and offtarget glycation. The detriment of intraday hyperglycaemia applies even in individuals with acceptable levels of HbA 1c , who might be subject to multiple peaks and troughs throughout the day despite apparently sufficient metabolic control [156] [157] [158] . Current antidiabetic options, insulin in particular, frequently subject patients to these large variations in levels of glucose. This phenomenon has not been observed in preclinical FGF1 studies thus far.
Along with large glycaemic swings, the contribu tion of T2DM to macrovascular complications can also be attributed to disruptions in PPARγ pathways that promote inflammation via vascular endothelial cells 159, 160 . As already discussed, FGF1 works along the PPARγ axis. Hepatically, rFGF1 is able to reduce inflammation; thus, by extension, rFGF1 could confer similar benefits on the cardiovascular system 161 . Furthermore, the ability of peripherally injected FGF1 to relieve insulin resist ance 8 and normalize levels of insulin in patients with T2DM would logically be expected to reduce the risk of stroke 162, 163 , diabetic retinopathy and hypertension 164 .
Limitations of the current data
The failure of central FGF1 to work in DIO mice raises a major concern as to whether it would be effective in patients with T2DM and obesity. Alas, data on peripheral or central actions of FGF1 in humans or nonhuman pri mates are not currently available. It is therefore impor tant to emphasize that most of the findings discussed in this Review were obtained from work performed in rodents; any extrapolation to humans must be done so critically. Despite the vast amount of knowledge obtained from animal models, only a finite number of antidia betic drugs in preclinical development have successfully advanced to clinical use. To some extent, speciesspecific variations in glucose regulation can be blamed for the limited interspecies translatability. Notable examples include differences in the major site of peripheral glu cose disposal, the liver in rodents and skeletal muscle in humans. Differences also exist in the hepatic glucose production rate, islet architecture, islet innervation and glucose sensing by pancreatic β cells 165, 166 . Species differences on a genomic and proteomic level, as well as deviations in pathway engagement, have been described with regards to glucose sensing in pancreatic β cells, which suggests a similar scenario for their central counterparts 165 . Furthermore, inbred diabetic mouse or rat models are often diabetic of monogenetic origin that is present from birth. These strains acquire rapid onset of obesity early in life mainly owing to hyperphagia and decreased energy expenditure, with only moderate vas cular and inflammatory complications. These models thus do not fully reflect the multifactorial disease aetio logy in humans, in which environmental influences are superimposed on genetic risk factors, and disease onset is more gradual and confounded by microvascular and macrovascular defects 167, 168 . This limitation is par ticularly relevant in the development and treatment of T2DM. With the jury still out on the actions of FGF1 on the HPA axis, one must also consider that the adverse effects of toxic glucose analogues such as STZ (which are used for the induction of a diabetic pathophysiology in rodents) are not confined to the pancreas and include disruption to the HPA axis in their repertoire 169 .
Conclusions
Clear mechanistic understandings of the endogenous and pharmacologic actions of FGF1 have yet to be described. However, the remarkable ability of peripher ally delivered FGF1 to rapidly restore normal glycaemic levels in diabetic mouse models and function as an insu lin sensitizer, combined with the longevity in glucose control achieved with central delivery, alludes to exciting opportunities for entirely new therapeutic approaches in the treatment of T2DM. This enthusiasm will gain cred ibility with preclinical results in higherorder mammals and the development of truly nonmitogenic analogues.
